The mice experiment also revealed a decrease of amyloid-beta production and neuroinflammation because of a compound formulated by the company called COR388.
“Drugs targeting the bacteria’s toxic proteins have so far only shown benefit in mice, yet with no new dementia treatments in over 15 years it’s important that we test as many approaches as possible to tackle diseases like Alzheimer’s,” chief scientific officer David Reynolds from Alzheimer’s Research said.
